Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy.

Zacho H, Jochumsen MR, Langkilde NC, Mortensen JC, Haarmark C, Hendel HW, Jensen JB, Petersen LJ.

J Nucl Med. 2019 May 30. pii: jnumed.119.229062. doi: 10.2967/jnumed.119.229062. [Epub ahead of print]

PMID:
31147402
3.

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.

Wondergem M, van der Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, Pruim J.

World J Urol. 2018 Jan;36(1):27-34. doi: 10.1007/s00345-017-2096-3. Epub 2017 Oct 17.

4.

Diagnostic test accuracy study of 18F-sodium fluoride PET/CT, 99mTc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer.

Fonager RF, Zacho HD, Langkilde NC, Fledelius J, Ejlersen JA, Haarmark C, Hendel HW, Lange MB, Jochumsen MR, Mortensen JC, Petersen LJ.

Am J Nucl Med Mol Imaging. 2017 Nov 1;7(5):218-227. eCollection 2017.

5.

A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.

Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.

J Nucl Med. 2017 Nov;58(11):1778-1785. doi: 10.2967/jnumed.116.189183. Epub 2017 Aug 10.

6.

Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.

Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA.

Ann Oncol. 2015 Oct;26(10):2113-8. doi: 10.1093/annonc/mdv289. Epub 2015 Jul 22.

7.

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI.

Clin Nucl Med. 2012 Jul;37(7):637-43. doi: 10.1097/RLU.0b013e318252d829.

8.

Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer.

Fonager RF, Zacho HD, Langkilde NC, Fledelius J, Ejlersen JA, Hendel HW, Haarmark C, Moe M, Mortensen JC, Jochumsen MR, Petersen LJ.

Acta Oncol. 2018 Aug;57(8):1063-1069. doi: 10.1080/0284186X.2018.1438651. Epub 2018 Feb 15.

PMID:
29447047
9.

Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer.

Sarikaya I, Sarikaya A, Elgazzar AH, Caloglu VY, Sharma P, Baqer A, Caloglu M, Alfeeli M.

World J Nucl Med. 2018 Oct-Dec;17(4):281-285. doi: 10.4103/wjnm.WJNM_87_17.

10.

Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.

J Nucl Med. 2015 Dec;56(12):1862-8. doi: 10.2967/jnumed.115.162610. Epub 2015 Sep 24.

12.

Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M.

Acta Oncol. 2016;55(1):59-67. doi: 10.3109/0284186X.2015.1027411. Epub 2015 Apr 2.

PMID:
25833330
13.

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.

Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1884-1897. doi: 10.1007/s00259-018-4058-4. Epub 2018 Jun 6.

PMID:
29876619
14.

Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.

Poulsen MH, Petersen H, Høilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J, Steffansen SI, Walter S.

BJU Int. 2014 Dec;114(6):818-23. doi: 10.1111/bju.12599. Epub 2014 May 22.

15.

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H.

AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.

PMID:
23096187
16.

Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.

Iagaru A, Mittra E, Dick DW, Gambhir SS.

Mol Imaging Biol. 2012 Apr;14(2):252-9. doi: 10.1007/s11307-011-0486-2.

PMID:
21479710
17.

The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.

Kulshrestha RK, Vinjamuri S, England A, Nightingale J, Hogg P.

J Nucl Med Technol. 2016 Dec;44(4):217-222. Epub 2016 Sep 15. Review.

18.

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.

J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.

19.

A proof-of-concept study analyzing the clinical utility of fluorine-18-sodium fluoride PET-CT in skeletal staging of oncology patients with end-stage renal disease on dialysis.

Usmani S, Marafi F, Esmail A, Ahmed N.

Nucl Med Commun. 2017 Dec;38(12):1067-1075. doi: 10.1097/MNM.0000000000000759.

PMID:
28953207
20.

Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.

Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Quinn B, Coleman RE.

J Nucl Med. 2014 Jul;55(7):1054-61. doi: 10.2967/jnumed.113.135475. Epub 2014 May 12.

Supplemental Content

Support Center